Blog - Advanced Medicine In China

3 months ago

FDA Yescarta (Axicabtagene Ciloleucel, Axi-Cel) Approval for Large B-Cell Lymphoma on April 1, 2022

FDA Yescarta (Axicabtagene Ciloleucel, Axi-Cel) Approval for Large B-Cell Lymphoma on April 1, 2022 On April 1, 2022, the FDA announced the approval of a new second-line treatment indication for Ax...

3 months ago

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~ mRNA Vaccine Tumor immunotherapy, as ...

3 months ago

On May 27, 2022, FDA Tisagenlecleucel Accelerated Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma After ≥ 2 Lines of Systemic Therapy

On May 27, 2022, FDA Tisagenlecleucel Accelerated Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma After ≥ 2 Lines of Systemic Therapy On May 27, 2022, the U.S. Food and Dru...

3 months ago

Why FDA Tecartus Suddenly Deleted the Warning Letter on January 23, 2024

Why FDA Tecartus Suddenly Deleted the Warning Letter on January 23, 2024 After the FDA issued a safety labeling change notification to all commercial CAR-T therapy manufacturers, Tecartus received ...

3 months ago

On April 1, 2022, FDA Approved Yescarta for Second-line Treatment of Large B-cell Lymphoma

On April 1, 2022, FDA Approved Yescarta for Second-line Treatment of Large B-cell Lymphoma On April 1, 2022, Kite, a subsidiary of Gilead Sciences, announced that the U.S. Food and Drug Administrat...

3 months ago

Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%

Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1% Gastric Cancer According to a report by People’s Daily on A...

3 months ago

IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy

###IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy IMWG ###EquecabtageneAutoleucel: Leading China’s CAR-T Therapy to Glob...

3 months ago

Approved Indications for EMA Yescarta Diffuse Large B-cell Lymphoma (DLBCL) and Advanced B-cell Lymphoma (HGBL) on October 17, 2022

Approved Indications for EMA Yescarta Diffuse Large B-cell Lymphoma (DLBCL) and Advanced B-cell Lymphoma (HGBL) on October 17, 2022 On October 17, 2022, exciting news came from the European Commiss...

4 months ago

Tumors Vanish After One Year of Treatment! The First Advanced Gastric Cancer Patient to Receive the New Cancer Vaccine Achieves Lasting Remission

**Tumors Vanish After One Year of Treatment! The First Advanced #GastricCancer Patient to Receive the New #Cancer Vaccine Achieves Lasting Remission** Cancer Vaccine Mrs. Liu, who was battling ad...

4 months ago

EMA Tecartus (Brexucabtagene Autoleucel) Approved for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) on December 17, 2020

EMA Tecartus (Brexucabtagene Autoleucel) Approved for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) on December 17, 2020 On December 17, 2020, Gilead’s subsidiary Kit...

4 months ago

Overview of EMA Kymriah (Tisagenlecleucel) Approval

Overview of EMA Kymriah (Tisagenlecleucel) Approval Introduction Kymriah (tisagenlecleucel), formerly known as CTL019, is a groundbreaking CAR-T cell therapy that has revolutionized the treatment l...

4 months ago

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma Multiple Myeloma In recent years, CAR-T cell therapy has made groundbreaking pr...

Menu

Our Blog